Articles tagged with Cancer Cells
A recent study by Sanford Burnham Prebys and the National Cancer Institute has shown that CRISPR-Cas9 gene editing can favor cells with mutated forms of genes linked to cancer. This highlights the importance of monitoring patients undergoing CRISPR-based gene therapy for cancer-related mutations.
Researchers at University of Göttingen investigate tight junctions' importance in cell movement and their consequences when missing. The findings suggest a 'tug of war' scenario between cells with unequal contraction and stretching, affecting tissue mobility and biological functions.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A research team at the University of Montreal Hospital Research Centre has found that cellular aging is caused by irreversible damage to the genome, not just telomere erosion. This discovery challenges the long-held scientific model and opens up new research opportunities for preventing cellular aging and genomic instability.
Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.
Researchers discovered a new biomarker, inactive AMPK (lo-P-AMPK), that may predict immune evasion in lung cancer. The finding could enable better personalized care for lung cancer patients by identifying those most likely to benefit from immunotherapies.
A new machine learning model developed by Timothy Chan accurately predicts whether immune checkpoint blockade will be effective in patients with various cancers. The tool assesses multiple patient-specific factors, including tumor mutational burden and chemotherapy history, to predict response and survival outcomes.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
Researchers are developing a transformative technology called Multiscale Intelligent Convergence (MusIC) to map the complexity of T cells and identify attributes essential for patient benefit. The goal is to create more reliable biomanufacturing of T cell infusion products and engineering potent immune cells.
Researchers discovered that pancreatic injury leads to the formation of new cell types that can give rise to cancerous mutations. The study provides a valuable resource for understanding the processes behind pancreatic cancer and potential therapeutic targets.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
Researchers developed a new NMR spectroscopic method to map IDP function more easily, fast, and accurately. The method sheds light on mechanisms of diseases like Parkinson's, Alzheimer's, and type 2 diabetes.
Researchers describe how cancer cells exploit genetic and cellular processes to promote tumor survival and growth. The study found that aneuploidy, a condition of abnormal chromosome number, intersects with the stress response mechanism in cancer cells, leading to immune cell dysregulation.
A new study identifies three functional subtypes of cancer-associated fibroblasts (CAF) in lung cancer, which correspond to patients' treatment responses. These subtypes have distinct biological functions and therapeutic implications, suggesting that CAFs could serve as a key to enhancing personalized treatment for lung cancer patients.
Researchers discovered cells can regulate neighboring cell stiffness to facilitate movement, a finding that could aid in understanding developmental disorders and cancer metastasis. This novel mechanism may provide a strategy for slowing or preventing cancer spread by altering tissue stiffness.
Researchers have developed nanoparticles that can communicate with and slow the development of cancer cells. The nanoparticles aggregate in cancer cells, reducing metabolic activity and growth, and are activated by MMP-9 enzyme secreted by cancer cells.
Researchers create maps of senescence in heart and lung cells, comparing different types of senescent cells across the lifespan. The goal is to understand how senescent cells contribute to age-related diseases and develop therapies called senolytics.
Researchers at Yale Cancer Center are launching a new tissue mapping center to study the role of senescent immune cells in development, aging, and disease. The goal is to develop strategies to target senescent cells to battle aging and cancer.
Researchers discovered that leukemia cells immediately unresponsive to treatment have high levels of SAMHD1, while those with acquired resistance use the enzyme DCK to activate nucleoside analogues. This finding may lead to better cancer therapies.
Scientists at the University of Cambridge have found that T cell mitochondria regulate the refuelling of toxic weapons, enabling killer T cells to stay healthy and keep killing. This discovery sheds light on how these immune system assassins are able to sustain their deadly missions.
A team of scientists from the University of Pittsburgh and National Cancer Institute discovered why HIV is rarely the direct cause of cancer. The research found that it requires a specific series of events involving changes in HIV and additional mutations in human genes, resulting in T cell lymphomas. However, the occurrence is rare, a...
Researchers used CRISPR/dCas9 technology to target DNA methylation and study its effects on cancer cell behavior. The study found that the same epigenetic modification can lead to opposing expression profiles of a target gene in different cancer cell models.
Researchers have discovered a way to bring cancer-killing T cells to bear against a specific type of colorectal cancer, showing promising results. The findings may represent a therapeutic strategy to target other types of cancers, and the next step is to further explore how T cells become activated in the tumor environment.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.
A new study at Ohio State University's Comprehensive Cancer Center is using rapid autopsies to gather biological samples after death to better understand how cancer cells overcome different treatments. This approach has already led to novel findings about drug resistance mechanisms, including the recent approval of a targeted therapy f...
A study by Weill Cornell Medicine identified Oct2 as the key determinant of B-cell humoral immune response, suggesting that the destiny of antibody-producing cells is predetermined. This discovery may lead to new insights into tissue development and cancer development.
Researchers at Johns Hopkins Kimmel Cancer Center discovered differences in gene activity between immune cells from patients with lung cancer who responded and did not respond to immunotherapies. The findings suggest that non-responders' immune cells can be reprogrammed to act more like responders', potentially leading to new treatment...
Researchers from FAU and MIT develop a microfluidic assay to study the mechanical performance of red blood cells under hypoxic conditions. The study reveals that cyclic hypoxia can lead to mechanical degradation of the red blood cell membrane, contributing to aging.
Researchers at Weill Cornell Medicine identified club cell factors that inhibit immunosuppressive cells in tumors, leading to increased antitumor T cells and improved effectiveness of PD1 immunotherapy. A
Researchers at Uppsala University developed a new method to track individual cancer cells and their offspring over time. The study found that brain tumour cells are hierarchically organised, but with some degree of flexibility, and that drug treatment influences cell organisation. This breakthrough may lead to the development of target...
Researchers at Université de Montréal and McGill University have discovered a new multi-enzyme complex that reprograms metabolism and overcomes cellular senescence. The enzyme complex, named HTC, can inhibit cells from aging and has potential applications in treating various cancers.
Researchers discover that tumor suppressor genes can prevent the immune system from spotting and destroying malignant cells in mice. The study reveals a surprising new action for many of these defective genes, which trigger mechanisms that prevent the immune system's T-cells from targeting tumors.
Scientists from Hungary, Russia, and Finland created SpheroidPicker, an AI device that selects cancer cells of specific shape and size. The system enables a more standardized approach to working with tumour samples, producing a more realistic response to treatments.
Researchers identified DNA mutations from platinum-based chemotherapies in AML patients, suggesting treatment-associated cancer development. The study's findings imply that clonal hematopoiesis precedes chemotherapy exposure.
Researchers at MIT developed a new way to grow pancreatic organoids using synthetic gel, allowing for study of interactions between tumors and environment. The gel can also be used to grow other types of tissue, including intestinal and endometrial tissue.
Researchers at UNSW Sydney have found the specific protein responsible for keeping cells attached to collagen, a key finding for cancer research. The discovery could lead to new directions for cancer treatment by targeting the protein tropomyosin, which is involved in forming the anchor's chain.
Researchers identify molecular targets for improved prostate cancer therapy by comparing genomic changes in cancer cells eradicated and resistant to treatment. The study also finds L1 retrotransposition as a dynamic source of cancer heterogeneity.
CD8+ T cell priming in the spleen generates long-lived, stem-like memory T cells with enhanced ability to differentiate into T effector cells. Spleen-primed T cells have superior capacity to respond to rechallenge infection and expand into infection-fighting T effector cells.
Researchers have created a new technology to enhance therapeutic antibodies' ability to attack blood cancer cells by leveraging the human immune system. This approach combines IgM and IgG antibodies, resulting in a single molecule with increased complement activation.
Despite its promise, cancer immunotherapy faces several hurdles, including limited efficacy and variable outcomes. Researchers are exploring new therapeutic targets and combination strategies to overcome resistance and improve patient outcomes.
Researchers from Charité and the German Cancer Consortium studied colorectal cancer cells using single cell sequencing to identify adaptations that render treatment ineffective. The study provides insights into the development process of cancer and suggests ways to improve current treatment approaches.
Silent mutations, which don't change protein sequences, hold diagnostic value in predicting cancer types and patient survival. The study analyzed over 10,000 cancer genomes and found that combining information from silent and non-silent mutations improved classification and prognostication up to 17% and 5%, respectively.
Researchers have found that viruses like hepatitis B and C do not always kill infected cells, but instead cause long-term changes. These changes can affect genes related to cell division and metabolism, potentially contributing to increased risk of liver cancer in cured patients.
A CRISPR screening tool identified ZMYND8, an epigenetic regulatory protein, as a potential new therapeutic target for acute myeloid leukemia. Inhibiting ZMYND8 has been shown to leave cancer cells with smaller tumors and better survival in mouse models.
Researchers at the University of Huddersfield have developed a new approach to combat cancer treatment challenges by creating self-assembled drugs with high specificity towards human cancer cells. The breakthrough demonstrates unprecedented anti-cancer activity and selectivity in laboratory testing.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
Researchers uncover how cancer cells make lactic acid to thrive in low-oxygen environments, a process enabled by the PRL-3 protein. This discovery holds promise for developing inhibitors to disrupt this survival mechanism.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
Researchers have discovered that inhibiting the GOT1 enzyme can promote ferroptosis, a type of programmed cell death, in pancreatic cancer cells by conserving nutrients and releasing iron stores. This study provides a new potential therapeutic target for treating pancreatic cancer.
Researchers at SMU found that decreasing TIGAR protein levels in cervical cancer cells makes them more responsive to chemotherapy drugs at low doses. This discovery offers a potential new treatment approach for HPV-induced cervical cancer with fewer side effects.
Researchers at Massachusetts General Hospital uncover key factors that enable immune cells to survive in tumor environments, including the chemokine CXCL16. This understanding may lead to more effective immunotherapies for cancer patients.
Researchers found that esomeprazole inhibits tumor growth and boosts the killing effect of radiation in various cancer cell types. Esomeprazole works by arresting cells in the G1 phase of the cell cycle, thereby limiting their ability to proliferate.
Researchers at UB aim to reduce unwanted toxicity in cancer treatments by combining antibody-drug conjugates with payload-binding selectivity enhancers. The five-year study may lead to safer and more effective treatments for 1.8 million US cancer patients.
Research has found that cancer cells develop resistance to platinum-based cytotoxic drugs by altering their communication with the surrounding extracellular matrix. This change allows the cancer cells to withstand the damage caused by the treatment and survive the chemotherapeutic attack.
Researchers have identified a promising therapeutic target, METTL1, to treat aggressive cancers by inhibiting an RNA-modifying protein. The study found that targeting METTL1 effectively destroys cancer cells in laboratory models and mice while leaving healthy cells unharmed.
Researchers from ETU LETI proposed an ensemble-based classification model using three Convolutional Neural Network architectures to detect cervical cancer. The model achieved high accuracy rates of up to 99.23% on publicly available benchmark datasets, outperforming state-of-the-art models.
Researchers found that microscopic defects in healthy cell alignment can slow down tumor cell invasion. The study used an experimental model to show how topological defects affect the rate of tumor cell invasion, with certain defects causing cancer cells to pass through the barrier more slowly.
Studies of cell-free DNA (cfDNA) shed into the blood reveal that modifications, such as methyl groups, can identify specific cell types. This allows for non-invasive assessment of tissue damage and origin, enabling researchers to evaluate treatment effectiveness and detect adverse effects.